Stanley Malkowicz, MD
Urology · Philadelphia, PANPI 1750337580
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $750 of the $952 with a category attached, or 78.8%. Davol Inc. accounts for 78.8% of it on its own, with 4 other manufacturers making up the rest. That places this record below the midpoint for urology clinicians in PA, where the typical reported total is $2,187.
Across 5 payments — averaging $190.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Davol Inc.$750
- Olympus America Inc.$117
- AstraZeneca$35
- Ferring Pharmaceuticals Inc.$25
- Coloplast$25
Across 116 payments — averaging $7591.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$881K
What the payments were for
- Speaking & faculty fees$75079%
- Food & beverage$16718%
- Education$354%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Davol Inc. | 1 | $750 |
| Olympus America Inc. | 1 | $117 |
| AstraZeneca | 1 | $35 |
| Ferring Pharmaceuticals Inc. | 1 | $25 |
| Coloplast | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iTIND System$117
How this compares
$952 in reported general payments places this provider in the 30th percentile of 596 urology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dutasteride | 20 | $378 |
Paid to pharmacies, not to this prescriber.
Other urology in Philadelphia
- Demetrius BagleyPhiladelphia$739K
- Daniel EunPhiladelphia$226K
- Leonard GomellaPhiladelphia$190K
- Phillip GinsbergPhiladelphia$145K
- Edouard TrabulsiPhiladelphia$137K
- Siobhan HartiganPhiladelphia$121K
- Paul ChungPhiladelphia$120K
- William JaffePhiladelphia$119K
- Robert UzzoPhiladelphia$111K
- Jay SimhanPhiladelphia$110K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.